Princeton, NJ, USA. November 9, 2017 – Promius Pharma LLC announced today the enrollment of subjects into the phase 3 clinical trials of DFD-03, a tazarotene formulation for the treatment of mild to moderate acne vulgaris.
“Promius Pharma’s development of novel pipeline assets to treat conditions like acne vulgaris is encouraging,” said Dr. Linda Stein Gold, Director of Dermatology Clinical Research at Henry Ford Health System in Detroit, MI. “Research is critical to providing patients with the treatment options of the future.”
This short-contact formulation is expected to bring a new dimension to the treatment of acne patients.